News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
707,968 Results
Type
Article (40440)
Company Profile (274)
Press Release (667253)
Multimedia
Podcasts (64)
Webinars (14)
Section
Business (205225)
Career Advice (2024)
Deals (35571)
Drug Delivery (98)
Drug Development (81345)
Employer Resources (172)
FDA (16284)
Job Trends (14946)
News (346812)
Policy (32720)
Tag
Academia (2574)
Accelerated approval (10)
Adcomms (22)
Allergies (95)
Alliances (49918)
ALS (109)
Alzheimer's disease (1453)
Antibody-drug conjugate (ADC) (154)
Approvals (16279)
Artificial intelligence (313)
Autoimmune disease (29)
Automation (19)
Bankruptcy (364)
Best Places to Work (11659)
BIOSECURE Act (20)
Biosimilars (124)
Biotechnology (190)
Bladder cancer (95)
Brain cancer (34)
Breast cancer (369)
Cancer (2893)
Cardiovascular disease (213)
Career advice (1694)
Career pathing (30)
CAR-T (188)
CDC (30)
Cell therapy (507)
Cervical cancer (22)
Clinical research (67013)
Collaboration (1030)
Company closure (3)
Compensation (690)
Complete response letters (23)
COVID-19 (2641)
CRISPR (58)
C-suite (333)
Cystic fibrosis (114)
Data (3015)
Decentralized trials (2)
Denatured (23)
Depression (63)
Diabetes (347)
Diagnostics (6447)
Digital health (23)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (140)
Drug pricing (124)
Drug shortages (28)
Duchenne muscular dystrophy (130)
Earnings (87603)
Editorial (40)
Employer branding (21)
Employer resources (148)
Events (114271)
Executive appointments (854)
FDA (17954)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (942)
Gene editing (133)
Generative AI (22)
Gene therapy (378)
GLP-1 (787)
Government (4518)
Grass and pollen (4)
Guidances (182)
Healthcare (18860)
HIV (40)
Huntington's disease (31)
IgA nephropathy (39)
Immunology and inflammation (153)
Immuno-oncology (9)
Indications (39)
Infectious disease (2815)
Inflammatory bowel disease (153)
Inflation Reduction Act (12)
Influenza (63)
Intellectual property (120)
Interviews (312)
IPO (16624)
IRA (47)
Job creations (3672)
Job search strategy (1436)
Kidney cancer (13)
Labor market (53)
Layoffs (502)
Leadership (19)
Legal (7967)
Liver cancer (79)
Longevity (11)
Lung cancer (402)
Lymphoma (209)
Machine learning (11)
Management (58)
Manufacturing (392)
MASH (91)
Medical device (13476)
Medtech (13481)
Mergers & acquisitions (19667)
Metabolic disorders (852)
Multiple sclerosis (97)
NASH (16)
Neurodegenerative disease (118)
Neuropsychiatric disorders (33)
Neuroscience (2139)
NextGen: Class of 2025 (6553)
Non-profit (4499)
Now hiring (48)
Obesity (428)
Opinion (221)
Ovarian cancer (101)
Pain (108)
Pancreatic cancer (124)
Parkinson's disease (186)
Partnered (22)
Patents (303)
Patient recruitment (167)
Peanut (50)
People (58035)
Pharmaceutical (67)
Pharmacy benefit managers (21)
Phase I (20898)
Phase II (29522)
Phase III (21960)
Pipeline (1648)
Policy (205)
Postmarket research (2564)
Preclinical (8908)
Press Release (64)
Prostate cancer (140)
Psychedelics (37)
Radiopharmaceuticals (253)
Rare diseases (465)
Real estate (5963)
Recruiting (66)
Regulatory (22715)
Reports (50)
Research institute (2333)
Resumes & cover letters (351)
Rett syndrome (9)
RNA editing (9)
RSV (49)
Schizophrenia (86)
Series A (162)
Series B (109)
Service/supplier (13)
Sickle cell disease (60)
Special edition (18)
Spinal muscular atrophy (148)
Sponsored (32)
Startups (3643)
State (2)
Stomach cancer (14)
Supply chain (76)
Tariffs (58)
The Weekly (39)
Vaccines (783)
Venture capital (56)
Weight loss (258)
Women's health (47)
Worklife (16)
Date
Today (86)
Last 7 days (367)
Last 30 days (1820)
Last 365 days (31279)
2025 (16987)
2024 (35333)
2023 (40181)
2022 (51288)
2021 (55836)
2020 (54155)
2019 (46642)
2018 (35124)
2017 (32224)
2016 (31629)
2015 (37706)
2014 (31454)
2013 (26499)
2012 (28770)
2011 (29426)
2010 (27526)
Location
Africa (723)
Alabama (61)
Alaska (7)
Arizona (244)
Arkansas (13)
Asia (38435)
Australia (6281)
California (7486)
Canada (2367)
China (674)
Colorado (322)
Connecticut (319)
Delaware (192)
Europe (82645)
Florida (1122)
Georgia (248)
Hawaii (1)
Idaho (60)
Illinois (646)
India (28)
Indiana (362)
Iowa (17)
Japan (229)
Kansas (110)
Kentucky (29)
Louisiana (14)
Maine (64)
Maryland (1028)
Massachusetts (5565)
Michigan (246)
Minnesota (454)
Mississippi (3)
Missouri (90)
Montana (28)
Nebraska (25)
Nevada (81)
New Hampshire (67)
New Jersey (2086)
New Mexico (28)
New York (2092)
North Carolina (1083)
North Dakota (8)
Northern California (3293)
Ohio (239)
Oklahoma (16)
Oregon (35)
Pennsylvania (1618)
Puerto Rico (17)
Rhode Island (36)
South America (1101)
South Carolina (34)
South Dakota (1)
Southern California (2805)
Tennessee (126)
Texas (1135)
United States (27729)
Utah (220)
Virginia (188)
Washington D.C. (73)
Washington State (638)
West Virginia (4)
Wisconsin (66)
707,968 Results for "sangamo biosciences inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Gene therapy
Sangamo’s ‘Positive’ Phase I/II Data for Fabry Gene Therapy Opens Path to FDA
Isaralgagene civaparvovec is a “potential best-in-class gene therapy for Fabry disease,” according to analysts at H.C. Wainwright. Sangamo plans to use pivotal Phase I/II data to build an accelerated approval case for the asset.
June 24, 2025
·
3 min read
·
Tristan Manalac
Gene therapy
Lilly Throws Sangamo a Lifeline With Pact Worth Potential $1.4B+
Sangamo, which has been having cash problems, will receive $18 million upfront in licensing fees for its AAV capsid that in preclinical studies has shown the ability to cross the blood-brain barrier.
April 4, 2025
·
2 min read
·
Tristan Manalac
Gene therapy
Sangamo’s Stock Plummets as Pfizer Axes Hemophilia Gene Therapy Pact
Sangamo is on course to run out of money within months and has now lost access to up to $220 million in milestone payments from Pfizer.
January 2, 2025
·
2 min read
·
Nick Paul Taylor
Press Releases
Messenger RNA Market Research Report 2025-2035, Competitive Analysis of Pfizer, GSK, Arcturus Therapeutics, AstraZeneca, Beam Therapeutics, Moderna, Oncotelic, SK Bioscience, Sangamo, Sanofi CureVac
June 11, 2025
·
6 min read
Press Releases
Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease
June 24, 2025
·
10 min read
Press Releases
Sangamo Therapeutics Announces First Quarter 2025 Earnings Call
May 6, 2025
·
1 min read
Press Releases
Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering
May 13, 2025
·
4 min read
Press Releases
Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day
May 13, 2025
·
1 min read
Press Releases
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results
May 12, 2025
·
17 min read
Regulatory
Sangamo’s Fabry Gene Therapy Could Hit Market 3 Years Earlier With FDA Accelerated Approval Pathway
The regulator agreed to allow Sangamo Therapeutics to use data to seek accelerated approval for its Fabry gene therapy candidate, eliminating the need for an additional registrational study and potentially shortening the time-to-market by three years.
October 23, 2024
·
2 min read
·
Tristan Manalac
1 of 70,797
Next
